Azilect tablets are taken by mouth for Parkinson’s disease, with the individual amount set according to each person’s treatment plan. Its active medicine, rasagiline mesylate, selectively inhibits…
Azilect tablets are taken by mouth for Parkinson’s disease, with the individual amount set according to each person’s treatment plan. Its active medicine, rasagiline mesylate, selectively inhibits monoamine oxidase-B to support dopamine activity and control Parkinsonian motor symptoms.
The active medicine, rasagiline mesylate, selectively inhibits monoamine oxidase-B to help preserve dopamine activity in the brain and support control of Parkinsonian motor symptoms.
Azilect is taken as an oral tablet. The amount per intake is selected individually rather than being a universal fixed dose for every patient.
Azilect can be taken with or without food, but a consistent routine makes missed doses less likely. Large amounts of foods rich in tyramine may require discussion when rasagiline is used with other medicines that affect monoamine metabolism, especially at higher exposure or in combination regimens.
Patients sometimes focus only on the tablet and forget that levodopa schedules can also affect the day’s movement pattern. A symptom diary recording stiffness, tremor, walking difficulty, involuntary movements, and timing of other Parkinson’s medicines can give the prescriber more useful information than a general statement that the medicine “worked” or “did not work.”
Rasagiline mesylate is converted to rasagiline, the pharmacologically active compound. Its main action takes place through selective inhibition of the MAO-B enzyme in the central nervous system.
Parkinson’s disease involves progressive dysfunction and loss of dopamine-producing neurons in the substantia nigra. Reduced dopamine signalling affects movement initiation, muscle tone, coordination, and the speed of voluntary movement. Azilect addresses one part of this pathway by slowing dopamine breakdown rather than replacing dopamine directly.
The amount per intake is set individually. Treatment decisions depend on symptom severity, other Parkinson’s medicines, age, kidney and liver function, and the person’s response over time.
Rasagiline selectively inhibits monoamine oxidase-B, an enzyme that metabolises dopamine in the brain. By reducing this breakdown, it increases the amount of dopamine available for signalling between nerve cells. This can improve movement-related symptoms, although it does not restore damaged nigrostriatal neurons or stop the underlying neurodegenerative process.
The effect is pharmacological support for the remaining dopamine pathways. It may help with slowness of movement, rigidity, tremor, and reduced motor function, while the exact response varies between patients. When levodopa is already part of treatment, rasagiline can provide additional dopaminergic support and may help reduce periods when symptoms return before the next levodopa dose.
MAO-B selectivity is dose-related. At higher exposures, selectivity can become less predictable, which helps explain why the prescribed amount must be followed rather than adjusted independently. The World Health Organization recognises Parkinson’s disease as a neurological disorder requiring long-term, individualised management, with medicines selected according to motor symptoms and treatment response [1].
Azilect tablets are taken by mouth for Parkinson’s disease, with the individual amount set according to each person’s treatment plan.
Azilect may form one part of a broader Parkinson’s treatment plan. Levodopa remains the most potent medicine for relieving many motor symptoms because it is converted into dopamine in the brain. Rasagiline works through a different mechanism, so clinicians may combine the two when levodopa alone does not provide sufficient control throughout the day.
Other medicines used in Parkinson’s disease include amantadine and dopamine agonists such as ropinirole. Combination products containing levodopa and a dopa-decarboxylase inhibitor may also be used. Stalevo combines levodopa, carbidopa, and entacapone; it can be part of a regimen in which an additional MAO-B inhibitor is considered, although the interaction profile must be reviewed carefully.
Adding rasagiline may improve wearing-off symptoms in some patients receiving levodopa. It can also increase dopaminergic adverse effects, including dyskinesia, hallucinations, orthostatic hypotension, or excessive sleepiness. When these appear, the solution may involve adjusting levodopa or another dopaminergic medicine rather than simply removing rasagiline.
Several habits can make treatment appear less useful or increase avoidable risk:
One mistake deserves special attention: patients may report “more tremor” while the real issue is wearing-off, dyskinesia, anxiety, or an unrelated illness. A short diary with medicine times and symptom times helps separate these patterns.
Fluoxetine and fluvoxamine require special attention because their long persistence in the body can affect the timing of a switch. Sertraline, citalopram, escitalopram, venlafaxine, tricyclic antidepressants, and St John’s wort also require a careful interaction assessment. Do not combine these products independently with rasagiline.
Dextromethorphan-containing cough medicines can pose a problem. Pethidine and tramadol are also unsuitable combinations because of the risk of serious central nervous system reactions. Sympathomimetic decongestants may require review in people with hypertension or cardiovascular disease.
Pregnancy and breastfeeding require a separate risk assessment because clinical experience is limited. Liver disease is significant because rasagiline exposure may increase when hepatic function is impaired.
Azilect is NOT for you if you have severe hepatic impairment or use interacting medicines without clinician review. Treatment may be ruled out or require a different plan if you are allergic to rasagiline, take another MAO inhibitor, use pethidine, tramadol, methadone, dextromethorphan, or certain antidepressants, or have had severe reactions, uncontrolled hallucinations, serious impulse-control symptoms, or sudden sleep episodes.
Do not combine these products independently with rasagiline. Pregnancy and breastfeeding also require a separate risk assessment, and liver disease matters because rasagiline exposure may increase when hepatic function is impaired.
Common or clinically recognised adverse effects can include headache, abdominal discomfort, nausea, dizziness, joint pain, and flu-like symptoms. When Azilect is combined with levodopa, dyskinesia may become more noticeable because the total dopaminergic effect increases.
Other important reactions include:
A person who becomes unusually sleepy should avoid driving and hazardous work until the symptom has been assessed. Hallucinations should not be dismissed as an unavoidable part of Parkinson’s disease; they may reflect the combined effect of several medicines.
One practical detail is often missed: constipation, dehydration, and blood-pressure-lowering medicines can make postural dizziness worse. Rising slowly, maintaining suitable fluid intake, and documenting faintness can help distinguish a medicine-related problem from ordinary morning unsteadiness.
Rasagiline and selegiline both inhibit MAO-B, but they differ in metabolism, dosing patterns, and available formulations. The choice depends on the treatment regimen, previous adverse effects, interactions, and the clinician’s treatment goals.
| Active ingredient | Pharmacological role | Formulation considerations |
|---|---|---|
| Rasagiline | Selective MAO-B inhibition | Oral tablet used alone or with other Parkinson’s medicines |
| Selegiline | MAO-B inhibition at prescribed Parkinson’s doses | Oral formulations with different absorption and metabolism characteristics |
Selegiline may produce metabolites with stimulant-like properties in some patients, which can matter when insomnia, anxiety, or cardiovascular symptoms are already present. Rasagiline has a different metabolic profile, yet it still carries important interaction restrictions because MAO-B inhibition can affect monoamine signalling.
These medicines are not interchangeable tablet-for-tablet. A change from one MAO-B inhibitor to another requires a deliberate schedule because overlapping treatment can increase the risk of excessive monoaminergic activity.
In clinical practice, neurologists usually assess Azilect by looking at function rather than by asking only whether tremor has disappeared. Walking speed, turning, getting out of a chair, dressing, handwriting, and the length of useful time between levodopa doses can all show whether the regimen is helping.
A prescriber would also review the full medicine list before adding rasagiline. Antidepressants, cough remedies, opioid analgesics, sedating medicines, and supplements can change the risk profile. The most useful follow-up information is specific: the time symptoms appear, what movement is difficult, whether dizziness occurs after standing, and whether sleepiness affects daily activities.
Rasagiline may help some patients without producing a dramatic sensation. A small reduction in morning stiffness or fewer wearing-off periods can still be clinically meaningful. The drawback is that improvements may be accompanied by dyskinesia, dizziness, hallucinations, or sleep disturbance when the combined dopaminergic load becomes too high.
A consistent time is usually the most practical choice, and many people take an oral Parkinson’s tablet in the morning to connect it with an established routine. The exact timing should fit the person’s other medicines and daily symptom pattern. EMA product information reviewed in 2025 supports oral administration with or without food, while individual schedules remain a clinical decision . Avoid changing the timing repeatedly because it makes symptom patterns harder to assess.
Pregnancy and breastfeeding require a specific assessment because clinical experience with rasagiline in these situations is limited. The potential need for Parkinson’s symptom control must be balanced against possible fetal or infant exposure. EMA safety information available through 2025 recommends careful evaluation rather than routine use in pregnancy or lactation. Breastfeeding plans should be discussed before treatment starts or before continuing an existing regimen.
Severe hepatic impairment is a concrete condition that can rule out rasagiline treatment because reduced liver function may raise exposure. The medicine also cannot be combined with certain MAO inhibitors, opioid analgesics, or other interacting drugs. Medsafe safety information from 2024 emphasises medicine-interaction review when monoamine metabolism is affected. Mild liver abnormalities do not automatically mean the same treatment decision, so the degree of impairment matters.
Azilect is intended for adults with Parkinson’s disease, and routine use in people under 18 is not established. Parkinson’s disease in childhood or adolescence requires specialist neurological assessment because the causes and treatment options differ from typical adult disease. EMA information reviewed in 2025 does not support treating children with rasagiline as a standard approach. Age alone should never be used to adapt an adult tablet schedule for a younger person.
Some antidepressants and supplements can interact with rasagiline by increasing serotonin or other monoamine activity. Examples requiring careful review include fluoxetine, fluvoxamine, venlafaxine, tricyclic antidepressants, and St John’s wort. WHO medicines-safety principles published in 2023 support checking the full medicine and supplement list before combining centrally acting treatments . Dextromethorphan cough products and opioid pain medicines such as tramadol also need specific attention.
Parkinson’s disease treatment is usually long term because symptoms persist and the underlying condition changes over time. The duration is not a fixed short course; it depends on benefit, adverse effects, disease stage, and the rest of the treatment plan. Clinical literature available through 2025 supports ongoing rasagiline use in selected adults when tolerability and symptom control remain acceptable . The regimen may still need adjustment if wearing-off, dyskinesia, hallucinations, or sleep problems develop.
Azilect can contribute to dyskinesia, especially when it is added to levodopa or another dopaminergic medicine. Dyskinesia means involuntary, often twisting or flowing movements that may appear when dopamine activity is high. EMA safety information reviewed in 2025 identifies dyskinesia among adverse effects reported with rasagiline treatment, with risk influenced by combination therapy . Recording when the movements occur helps the clinician decide whether to adjust rasagiline, levodopa, or another medicine.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 4 reviews
The main change was that my first dose seemed to carry me further into the morning. I still had stiffness, and the improvement was gradual rather than dramatic. I noticed extra finger movements after a few weeks, which settled after my neurologist adjusted the rest of my treatment.
Gisborne Several months 6 Oct 2026Walking to the shops became less tiring after the treatment had been established. I also felt light-headed when standing from the sofa, especially on warm days. Keeping track of blood pressure and drink intake helped the clinic understand what was happening.
Blenheim Several months 16 Oct 2026I found the once-daily routine easy to remember and felt less stuck when starting to walk. It did not remove the symptoms, and missing several doses made my routine feel unsettled. I was glad the neurologist asked about sleep because I had become unusually drowsy in the afternoon.
Hastings Several months 21 Oct 2026The wearing-off periods seemed shorter after the dose had been adjusted. The first weeks were frustrating because nausea and dizziness made me question the treatment. Those problems improved after the wider Parkinson’s prescription was reviewed, rather than by adding more tablets.
Greymouth Several weeks 3 Nov 2026
